IRIS
GOBBI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.139
AS - Asia 2.753
NA - Nord America 2.208
SA - Sud America 245
Continente sconosciuto - Info sul continente non disponibili 215
AF - Africa 27
OC - Oceania 7
Totale 34.594
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.610
US - Stati Uniti d'America 2.058
SG - Singapore 1.192
CN - Cina 717
VN - Vietnam 400
FR - Francia 234
BD - Bangladesh 205
BR - Brasile 155
FI - Finlandia 85
HK - Hong Kong 76
CA - Canada 59
DE - Germania 48
CH - Svizzera 44
AR - Argentina 34
JP - Giappone 31
MX - Messico 28
GB - Regno Unito 20
IN - India 19
IQ - Iraq 19
EC - Ecuador 18
JM - Giamaica 14
ES - Italia 13
UA - Ucraina 13
ID - Indonesia 12
NL - Olanda 12
CO - Colombia 10
HN - Honduras 10
RU - Federazione Russa 10
TR - Turchia 9
PH - Filippine 8
PL - Polonia 8
PY - Paraguay 8
TW - Taiwan 8
CR - Costa Rica 7
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
VE - Venezuela 7
CL - Cile 6
TT - Trinidad e Tobago 6
AU - Australia 5
GT - Guatemala 5
IE - Irlanda 5
NI - Nicaragua 5
SV - El Salvador 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
DZ - Algeria 4
GR - Grecia 4
JO - Giordania 4
PE - Perù 4
PR - Porto Rico 4
PT - Portogallo 4
RS - Serbia 4
TH - Thailandia 4
ET - Etiopia 3
KR - Corea 3
RO - Romania 3
AT - Austria 2
BG - Bulgaria 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GD - Grenada 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
KE - Kenya 2
MK - Macedonia 2
MM - Myanmar 2
MT - Malta 2
MY - Malesia 2
NO - Norvegia 2
QA - Qatar 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BE - Belgio 1
BY - Bielorussia 1
CU - Cuba 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
GF - Guiana Francese 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MZ - Mozambico 1
NC - Nuova Caledonia 1
OM - Oman 1
PA - Panama 1
PF - Polinesia Francese 1
SE - Svezia 1
SI - Slovenia 1
Totale 34.376
Salva come PNG Salva come JPEG
Città #
Genova 18.691
Genoa 5.876
Rapallo 2.346
Vado Ligure 1.426
San Jose 602
Singapore 538
Lauterbourg 214
Ashburn 201
New York 123
Ho Chi Minh City 107
Helsinki 85
Hanoi 84
Beijing 81
Hong Kong 71
Santa Clara 60
Bordighera 56
Frankfurt am Main 43
Los Angeles 43
Zurich 43
Chicago 29
Rome 26
Dallas 25
Tokyo 25
Milan 20
Atlanta 19
Montreal 19
Haiphong 18
Phoenix 18
São Paulo 18
Tianjin 18
Buffalo 16
Council Bluffs 16
Da Nang 15
Mexico City 14
Naples 14
Columbus 13
Orem 12
Amsterdam 11
Philadelphia 11
Toronto 11
Biên Hòa 9
Miami 9
Paris 9
Quito 9
Belo Horizonte 8
Chennai 8
Houston 8
Las Vegas 8
Louisville 8
San Antonio 8
Turin 8
Can Tho 7
Cardiff 7
Madrid 7
Baghdad 6
Boardman 6
Charlotte 6
Cleveland 6
Denver 6
Detroit 6
Florence 6
Kyiv 6
Newark 6
Seattle 6
Warsaw 6
Des Moines 5
Greensboro 5
Guatemala City 5
Jacksonville 5
Kingston 5
Memphis 5
Minneapolis 5
Nashville 5
Orland Park 5
Princeton 5
Queens 5
Quảng Ngãi 5
San Francisco 5
San José 5
San Salvador 5
Amman 4
Austin 4
Baku 4
Bari 4
Baton Rouge 4
Bologna 4
Bắc Giang 4
Cincinnati 4
City of London 4
Curitiba 4
Dublin 4
Guangzhou 4
Guayaquil 4
Hải Dương 4
Lawrenceville 4
London 4
Managua 4
Morón 4
Ninh Bình 4
Palermo 4
Totale 31.392
Salva come PNG Salva come JPEG
Nome #
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. 481
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 326
APO866 activity in hematologic malignancies: a preclinical in vitro study. 252
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 250
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts 244
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 228
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 227
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 220
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 219
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 215
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 211
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 210
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 205
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 204
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 200
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 199
M-2 protocol for melphalan-resistant and relapsing multiple myeloma. 199
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study 199
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 199
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 198
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 195
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 194
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 192
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 191
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 188
Randomized trial of Fludarabine versus fludarabine and Idarubicin as Frontline treatment in patients with indolent or mantle-cell lymphoma 185
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. 184
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor V? 2 T lymphocytes in non-Hodgkin lymphomas 183
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 182
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 180
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 179
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 177
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 177
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. 176
An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells. 176
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 175
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. 175
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 173
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 172
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 172
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 171
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 171
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 170
T lymphocyte subsets and colony growth in hairy-cell leukemia. 169
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 169
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 168
[Allogeneic bone marrow transplantation in multiple myeloma]. 168
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 167
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis 167
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 166
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 165
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. 164
Thalidomide in agnogenic and secondary myelofibrosis 161
IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia 161
An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. 161
An immunotoxin made up with campath 1 and saporin 6: preliminary "in vitro" experience. 160
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patients. 159
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 159
Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 159
An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) grows in SCID-mice with the features of a CD30+ anaplastic large cell lymphoma and is sensitive to anti-CD30 immunotoxins 158
Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report 158
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 157
A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. 156
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 156
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 156
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 155
HIV-related malignant lymphoma: a report of 46 cases observed in Italy. 155
Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. 155
Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. 154
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. 154
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 154
Targeting of a plasma cell line with a conjugate containing xanthine oxidase and the monoclonal antibody 62B1. 154
New insights into biology of chronic myeloid leukemia: implications in therapy. 154
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 153
Hodgkin's disease (HD): a historical perspective. 153
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 153
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. 151
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 151
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 150
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 150
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 149
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 149
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura 149
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 148
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor cell rescue for metastatic breast cancer 147
Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. 147
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 147
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 146
[Methods for studying pleiotropic drug resistance (multidrug resistance, MDR)]. 146
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma 145
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study. 145
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. 145
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 145
Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. 144
CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report. 144
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 144
T-cell depletion with the monoclonal antibody Campath 1 to prevent graft-versus-host disease in ten high-risk adult patients. 143
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 143
Laparoscopic splenectomy for hematological diseases. 142
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 142
Totale 17.594
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.282
article - articoli 99.071
book - libri 0
conference - conferenze 299
curatela - curatele 0
other - altro 387
patent - brevetti 0
selected - selezionate 0
volume - volumi 525
Totale 200.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.848 78 210 206 293 174 180 158 679 93 295 98 384
2022/20232.839 306 163 38 272 506 554 11 235 470 35 211 38
2023/20241.387 68 189 33 143 128 295 61 128 64 21 76 181
2024/20253.710 67 327 114 227 450 347 346 596 105 155 460 516
2025/20267.059 851 163 323 663 811 753 1.186 332 540 637 387 413
2026/2027700 700 0 0 0 0 0 0 0 0 0 0 0
Totale 34.594